2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

 St. Anton, Austria    January 19-23, 2020

Keynote Speakers

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)

Dr Lawrence G. HAMANN
Dr Lawrence G. HAMANN
BRISTOL-MYERS SQUIBB, Cambridge, United States
Read more

Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire (KL01)

Prof. Sarah E. REISMAN
Prof. Sarah E. REISMAN
CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States

Controlling the Fate and Function of Proteins with Photopharmacology (KL03)

Prof. Dirk TRAUNER
Prof. Dirk TRAUNER
NEW YORK UNIVERSITY, New York, United States
Read more

Accelerating Drug Discovery by Intelligence Augmentation

Exploring an Interface of Synthesis and Data Science (PL18)

Prof. Timothy CERNAK
Prof. Timothy CERNAK
UNIVERSITY OF MICHIGAN, Ann Arbor, United States
Read more

Organic Synthesis on a Computer: Should Medicinal Chemists Care? (PL17)

Prof. Bartosz A. GRZYBOWSKI
Prof. Bartosz A. GRZYBOWSKI
ULSAN NATIONAL INSTITUTE OF SCIENCE & TECHNOLOGY, Ulsan, Korea, South
Read more

Accelerating R&D with Augmented Intelligence (PL19)

Dr Matthias ZENTGRAF
Dr Matthias ZENTGRAF
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
Read more

Drug Discovery Tales

The Big Impact of Small Changes : Towards Best-in-Class EZH2 and LSD1 Inhibitors (OC08)

Dr Julian LEVELL
Dr Julian LEVELL
CONSTELLATION PHARMACEUTICALS, Cambridge, United States
Read more

Discovery of AZD3458 a Highly Selective PI3Ky Inhibitor: Combining Structure, HDX-MS and Binding Kinetics to Understand the Mode of Action (OC06)

Dr Nils PEMBERTON
Dr Nils PEMBERTON
ASTRAZENECA, Mölndal, Sweden
Read more

The Discovery of a Potent and Orally Bioavailable Macrocyclic Cyclophilin Inhibitor Based on The Structural Simplification of Sanglifehrin A (OC07)

Dr Vicky STEADMAN
Dr Vicky STEADMAN
EUROFINS DISCOVERY, Essex, United Kingdom
Read more

Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of IPF (OC05)

Dr James THOMPSON
Dr James THOMPSON
GLAXOSMITHKLINE/UNIVERSITY OF STRATHCLYDE, Stevenage, United Kingdom
Read more

Discovery of GDC-0334: a potent and orally bioavailable clinical candidate for the inhibition of TRPA1 (OC04)

Dr Vishal VERMA
Dr Vishal VERMA
GENENTECH, South San Francisco, United States
Read more

Frontiers of Synthetic Chemistry

A Radical Way to Abeo-Steroids (PL08)

Prof. Philipp HERETSCH
Prof. Philipp HERETSCH
FREE UNIVERSITY OF BERLIN, Berlin, Germany
Read more

New Avenues in Synthesis Enabled by Organic Photoredox Catalysis (PL06)

Prof. David NICEWICZ
Prof. David NICEWICZ
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States
Read more

Late-Stage Functionalizations (PL07)

Prof. Tobias RITTER
Prof. Tobias RITTER
MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany
Read more

Break-it-to-Make-it Strategies for Complex Molecule Synthesis (PL05)

Prof. Richmond SARPONG
Prof. Richmond SARPONG
UNIVERSITY OF CALIFORNIA, BERKELEY, Berkeley, United States
Read more

Innovation and Inspiration from Natural Products

Capturing Biological Activity in Natural Product Fragments: Success and Limitations (PL14)

Prof. Karl GADEMANN
Prof. Karl GADEMANN
UNIVERSITY OF ZÜRICH, Zürich, Switzerland
Read more

(De)Construction of Three-Dimensional Molecular Architectures (PL15)

Prof. Thomas MAGAUER
UNIVERSITY OF INNSBRUCK, Innsbruck, Austria

Synthesis of Complex Antiplasmodial Isocyanoterpenes (PL16)

Prof. Christopher VANDERWAL
Prof. Christopher VANDERWAL
UNIVERSITY OF CALIFORNIA, IRVINE, Irvine, United States
Read more

Total Synthesis of Chivosazole F (OC03)

Dr Simon WILLIAMS
Dr Simon WILLIAMS
SYNGENTA, Stein AG, Switzerland
Read more

Predictive ADME Sciences: Striking a Balance Between In Silico and Experimental Work?

Structural Attributes Influencing Unbound Tissue Distribution (PL01)

Dr Li DI
Dr Li DI
PFIZER, Groton, United States
Read more

Metabolism of Strained Rings: Tales of the Unexpected (PL02)

Dr Martin HAYES
Dr Martin HAYES
ASTRAZENECA, Gothenburg, Sweden
Read more

Predicting ADME - Reality, Vision or Fantasy? (PL04)

Dr Simone SCHADT
Dr Simone SCHADT
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Leveraging In Silico ADMET Profiles and Ancillary Pharmacology to Influence Prioritization of Hit Series with Higher Probability of Success (PL03)

Dr Falgun SHAH
Dr Falgun SHAH
MERCK & CO., West Point, United States
Read more

Dr Kenichi UMEHARA
Dr Kenichi UMEHARA
ROCHE PHARMACEUTICAL RESEARCH AND EARLY DEVELOPMENT, Basel, Switzerland
Read more

Protein Degradation: New Rules for Drug Discovery

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)

Dr Lawrence G. HAMANN
Dr Lawrence G. HAMANN
BRISTOL-MYERS SQUIBB, Cambridge, United States
Read more

Targeted Protein Degradation (PL12)

Prof. Andy PHILLIPS
Prof. Andy PHILLIPS
C4 THERAPEUTICS, Watertown, United States
Read more

Four E3 Ligases, One Target: Towards Novel CDK6 Protacs (OC02)

Mr Christian STEINEBACH
Mr Christian STEINEBACH
UNIVERSITY OF BONN, Bonn, Germany
Read more

Chemical Genomics Approaches to Targeted Protein Degradation (PL13)

Dr Georg WINTER
Dr Georg WINTER
RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES, Vienna, Austria
Read more

Structure and Biophysics - Companions for Medicinal Chemistry

Membrane Proteins at the SGC – Challenges and Success Stories (PL09)

Dr Katharina DUERR
Dr Katharina DUERR
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Discovery of Small Molecule Fascin 1 Inhibitors Using Fragment-Based Drug Discovery (OC01)

Dr Stuart FRANCIS
Dr Stuart FRANCIS
THE BEATSON INSTITUTE FOR CANCER RESEARCH, Glasgow, United Kingdom
Read more

The Mechanism of Outer Membrane Protein Insertion by BamA and its Role as a Target for Novel Antibiotic (PL10)

Prof. Sebastian HILLER
Prof. Sebastian HILLER
UNIVERSITY OF BASEL, Basel, Switzerland

Discovery of ABL001, an Allosteric Inhibitor of BCR-ABL: Fragments, Biophysics, Structure and Chemistry (PL11)

Dr Wolfgang JAHNKE
Dr Wolfgang JAHNKE
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

Targeted Delivery - Strategies to Help your Drug Substances get to the Right Place

Using Small Molecules to Engineer and Explore Human Immunity (PL20)

Prof. David SPIEGEL
Prof. David SPIEGEL
YALE UNIVERSITY, New Haven, United States
Read more

Intracellular and Tissue Specific Targeting of Therapeutic Modalities (PL22)

Dr Vadim DUDKIN
Dr Vadim DUDKIN
JANSSEN DISCOVERY SCIENCES, Lansdale, United States
Read more

SBT6050, a HER2-Directed TLR8 Immunotac™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity (PL23)

Dr Valerie ODEGARD
Dr Valerie ODEGARD
SILVERBACK THERAPEUTICS, Seattle, United States
Read more

Discovery of Tumor-Targeted TLR7/8 Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-Oncology Therapeutics (PL21)

Dr Brian SAFINA
Dr Brian SAFINA
BOLT BIOTHERAPEUTICS, Redwood City, United States
Read more